Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2020-08-13 Report Publication Anno…
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: Invitation to presentation of second quarter and first half year 2020 financial results
Report Publication Announcement Classification · 98% confidence The document is an invitation from Photocure ASA to a presentation regarding their 'second quarter and first half year 2020 financial results'. It explicitly states that the 'quarterly report and presentation will be published at 07:00 CET' and invites stakeholders to a presentation/streaming event later that day. Since the document's primary function is to announce the upcoming release of financial results and the associated presentation event, rather than being the full report itself (which would be an IR or ER), it fits the definition of a Report Publication Announcement (RPA). The document length is short (1872 chars), supporting the 'MENU VS MEAL' rule.
2020-08-13 English
Photocure appoints Genotests as exclusive partner for Hexvix[ ]in Chile
Regulatory Filings Classification · 95% confidence The document is a press release dated August 13, 2020, announcing a new exclusive distribution agreement between Photocure ASA and Genotests SpA for the commercialization of Hexvix in Chile. This type of announcement, detailing a strategic partnership or commercial development, does not fit the definitions for standard financial reports (10-K, IR, ER), regulatory filings (RNS), or specific corporate actions (DIV, SHA, POS). It is a general corporate update regarding business operations and market expansion. Since there is no specific category for 'Partnership Announcement' or 'Press Release', and it is not a report itself (it's an announcement), the most appropriate fallback category is 'Regulatory Filings' (RNS), as press releases often serve as general regulatory disclosures when a more specific category is unavailable. However, given the content is purely business development and not a mandatory financial filing, 'Regulatory Filings' (RNS) is the best fit among the provided options for a general corporate announcement.
2020-08-13 English
Photocure appoints Genotests as exclusive partner for Hexvix[ ]in Chile
Regulatory Filings Classification · 100% confidence The document is a press release dated August 13, 2020, announcing a specific business event: Photocure appointing Genotests as an exclusive distributor for Hexvix in Chile. This type of announcement, detailing commercial agreements, partnerships, or strategic business updates, does not fit the definitions for formal regulatory filings (10-K, IR, ER, etc.). It is a general corporate announcement. Since there is no specific category for 'Partnership Announcement' or 'Press Release', and it is not a report itself, a dividend notice, or a management change, the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous official announcements that do not fit elsewhere, although 'LTR' (Legal Proceedings Report) or 'MANG' (Board/Management Information) are clearly incorrect. Given the options, RNS is the best fit for a general, non-financial-result-focused corporate news release.
2020-08-13 English
Photocure's partner Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 (Cevira)
Regulatory Filings Classification · 95% confidence The document is a short press release (1510 characters) announcing a specific corporate event: Asieris (Photocure's partner) received approval from the NMPA to start a Phase III clinical trial for APL-1702. This is not a comprehensive financial report (like 10-K or IR), nor is it a standard earnings release (ER). It relates to product development and regulatory milestones, which often fall under general corporate updates. Since there is no specific category for 'Clinical Trial Approval Announcement' or 'Product Development Update,' and given the short length and the concluding sentence 'Please read the full release here,' it best fits the general regulatory/corporate announcement fallback category, RNS (Regulatory Filings), as it is a material, non-financial announcement.
2020-07-08 English
Photocure's partner Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 (Cevira)
Regulatory Filings Classification · 100% confidence The document is a short press release announcing that Photocure's partner, Asieris, received approval from the China NMPA to start a global Phase III clinical trial for a drug (APL-1702). It details regulatory milestones and clinical development plans. This type of announcement, which is not a full financial report (like 10-K or IR), nor a management change (MANG), nor a dividend notice (DIV), nor a director's dealing (DIRS), falls best under general regulatory or corporate news. Since it is a specific announcement about a regulatory/clinical development milestone, and it is very short (1759 chars) with a link to the 'full release', it is most appropriately classified as a general Regulatory Filing (RNS) or potentially a Legal/Regulatory update if the focus was on litigation, but RNS serves as the best general regulatory announcement fallback here, as it is not explicitly covered by other codes like CAP, LTR, or ER.
2020-07-08 English
Photocure appoints Susanne Strauss as Vice President and General Manager of Europe
Board/Management Information Classification · 98% confidence The document is a press release announcing the appointment of a new executive, Susanne Strauss, as Vice President and General Manager of Europe. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document does not contain comprehensive financial statements (10-K, IR), earnings highlights (ER), or a transcript (CT). Therefore, the appropriate classification is MANG.
2020-07-01 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.